The battle against superbugs

May 29, 2016

The sugar-loving Klebsiella pneumoniae, that resembles a squished-up earplug, can strike fear into the hearts of surgeons and scientists. The bacterium can repel even the most powerful antibiotics...

Spotlight

The Healthcare Performance Management Institute (HPMI), an independent research entity dedicated to providing research-based solutions, conducted a series of interviews with subject matter experts representing various segments of the healthcare industry...

Spotlight

The Healthcare Performance Management Institute (HPMI), an independent research entity dedicated to providing research-based solutions, conducted a series of interviews with subject matter experts representing various segments of the healthcare industry...

Related News

HEALTH TECHNOLOGY

Pure Health UAE Largest Healthcare Platform Signs a Deal With Equity Group Investments to Invest Half a Billion Dollars in a U.S. Healthcare Company

Pure Health | September 05, 2022

Alpha Dhabi Holding subsidiary, Pure Health, the largest integrated healthcare platform of the United Arab Emirates announced that it has entered into a definitive purchase agreement to acquire a minority equity investment in Ardent Health Services a leading U.S. healthcare provider based in Nashville, Tennessee, for a total investment of $500 million. The investment is subject to customary closing conditions and will be finalized after receipt of all necessary U.S. regulatory approvals. Ardent is the fourth largest privately held acute care hospital operator in the U.S., with 30 hospitals and more than 200 sites of care across six states, and approximately 26,000 employees. Pure Health would achieve a minority equity investment by purchasing an interest in Ardent from Equity Group Investments a Chicago-based private investment firm and majority owner of Ardent. As part of its investment, Pure Health would receive board observer rights but would not have a seat on Ardent’s board of directors. The investment does not include plans for either the expansion of Ardent’s physical footprint or collaboration between Ardent and Pure Health in the delivery of care. Equity Group Investments hosted a signing ceremony, which included Farhan Malik, CEO of Pure Health, Sam Zell, founder and chairman of EGI, and Marty Bonick, president and chief executive officer of Ardent. “One of EGI’s strengths is partnering with like-minded individuals with the experience and passion for how we approach investment opportunities. We look forward to developing a productive relationship with Pure Health as they continue to explore the various dynamics of the U.S. healthcare system,” Sam Zell Commenting on the major investment announcement, Farhan Malik said, “This landmark investment agreement marks a quantum leap for the UAE and the global healthcare industry.” “This is an exciting opportunity for Pure Health, as we continue to build relationships with leading U.S. healthcare providers to leverage the highest standards and best clinical practices to provide an unrivalled healthcare experience for patients in the UAE,” said Malik. “Ardent has a strong track record of delivering outstanding services across the United States, and we look forward to gaining additional knowledge to support our north star of advancing the science of longevity and unlocking time for humanity.” ABOUT PURE HEALTH Pure Health is an integrated healthcare solutions platform with a diversified portfolio of over 25 hospitals and more than 100 clinics offering 200+ specialties covering services from tertiary care to primary care; health insurance that covers over 2.5 million members; group procurement organization; over 150 laboratories; diagnostics services; rehab services; long term care; medical supplies; and health technology services. With more than 50 million annual clinical encounters and over 25,000 employee strength, the company provides healthcare services across the entire continuum of care. Pure Health is committed to enhancing longevity and helping people live longer, happier, and healthier lives. The company’s centers of excellence bring together clinical knowledge, process expertise, technology, and analytics to deliver outcome-focused, world-class quality across all channels of healthcare with a mandate to future-proof the healthcare system for a world of technological singularity. ABOUT EQUITY GROUP INVESTMENTS Equity Group Investments (EGI), founded by Sam Zell more than 50 years ago, has a long track record of building public and private businesses, including the origination and growth of multi-billion-dollar companies. EGI’s flexible capital and open investment mandate enable the firm to pursue opportunistic transactions across industries and geographies, throughout the capital structure, at any point in the economic cycle. EGI’s current portfolio includes investments in transportation and logistics, health care, manufacturing, agribusiness, energy, retail, waste and infrastructure, and real estate. ABOUT ARDENT HEALTH SERVICES Ardent Health Services invests in people, technology and communities. Through its subsidiaries, Ardent owns and operates 30 hospitals and more than 200 sites of care in six states with approximately 26,000 employees, including 1,200+ employed providers. With a focus on evidence-based practices to improve quality care and patient outcomes, four Ardent hospitals were named to Leapfrog’s Top Hospitals in 2021, and eight Ardent hospitals received a Leapfrog Hospital Safety Grade of A for Spring 2022. Based in Nashville, Tennessee, Ardent is owned by current and former members of Ardent’s management team; Equity Group Investments (EGI), a Chicago-based private investment firm; and Ventas, Inc.

Read More

HEALTH TECHNOLOGY

Perimeter Medical Imaging AI Announces Commercial Placement of Perimeter S-Series OCT within National Healthcare Provider System

Perimeter Medical Imaging AI, Inc. | September 30, 2022

Perimeter Medical Imaging AI, Inc. announced the commercial placement of its flagship Perimeter S-Series OCT system at a hospital that is part of a major national healthcare system and one of the largest healthcare networks in North Texas. Perimeter is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs. “This commercial placement of our Perimeter S-Series OCT system at a hospital in a major healthcare network marks a significant milestone for us as we gain traction validating our commercial model. Perimeter S-Series OCT aims to improve patient outcomes and lower healthcare costs, and we are excited that leading surgeons and hospitals are seeing the potential of our ground-breaking technology.” Jeremy Sobotta, Perimeter’s Chief Executive Officer About Perimeter Medical Imaging AI, Inc. Based in Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging AI (TSX-V:PINK) (OTC:PYNKF) (FSE:4PC) is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. Available across the U.S., our FDA-cleared Perimeter S-Series OCT system provides real-time, cross-sectional visualization of excised tissues at the cellular level, with 10x greater image resolution than X-ray and ultrasound, and 100x greater than MRI. The breakthrough-device-designated investigational Perimeter B-Series OCT with ImgAssist AI represents our next-generation artificial intelligence technology that is currently being evaluated in a pivotal clinical trial, with support from a grant of up to US$7.4 million awarded by the Cancer Prevention and Research Institute of Texas. The company’s ticker symbol “PINK” is a reference to the pink ribbons displayed during Breast Cancer Awareness Month.

Read More

HEALTH TECHNOLOGY

nference Launches AI-Driven Platform and Expands Partnership with Mayo Clinic, Offering Access to One of the Deepest Real-World

nference | September 22, 2022

nference, a science-first software company transforming healthcare by making biomedical data computable announced the launch of its AI-driven nSights platform, which will allow biopharma, medical device companies, and diagnostic firms to access and directly engage with curated, de-identified healthcare data to advance research and discovery. The company also expanded its exclusive 12-year strategic relationship with Mayo Clinic, providing nference partners and customers with access to Mayo Clinic Platform’s extensive de-identified electronic health data across a range of disease and therapeutic areas. This expanded collaboration will increase access to data-derived insights and knowledge by establishing a Mayo Clinic-branded version of nSights, called Mayo Clinic Platform_Discover, built and supported by nference to help its partners solve some of the most complex clinical challenges. nSights is a software platform that makes real-world data available across multiple data modalities (clinical, molecular, and imaging). The platform enables data exploration, hypothesis generation, analytics, and data science capabilities, including algorithm development, for users of all backgrounds. nSights provides a longitudinal, 360-degree view of each patient by leveraging an ensemble of biomedical information, such as electronic health records, electrocardiograms, radiology images and more. Future iterations will also include digital pathology and genomics. The platform is supported by a flexible data dictionary, allowing for the generation of new patient-level features for analysis. “The potential of electronic health data remains locked at medical centers and is frequently under-leveraged due to data complexity, privacy, and security concerns. Our expanded collaboration with Mayo Clinic Platform provides the framework for nference’s deployment of nSights and enables our customers to access de-identified ‘patient-level’ data to drive research and development of new therapeutics. I look forward to continuing to build and fortify our partnership with the Mayo Clinic team as we work together to improve healthcare through data-derived insights and knowledge.” Mike Koenig, chief commercial officer at nference As a result of the company’s partnerships with major academic medical centers like Mayo Clinic, nSights provides access to the deepest curated patient-level dataset available across all therapeutic areas, including cardiology, oncology, metabolic diseases, immunology, and infectious diseases. The platform offers insights from both structured and unstructured records, representing more than 20 years of longitudinality, including data from over 520 million clinical notes, 1.3 billion lab test results, 10.2 billion flowsheets, and more. “Over the past year, our collaboration with nference, leveraging nSights, has accelerated clinical decision support and care in significant ways," said Maneesh Goyal, chief operating officer, Mayo Clinic Platform. "Data-derived insights and knowledge help us accelerate and enhance innovation and meet the unmet needs of patients everywhere.” About nference Through its powerful technology platform and software, nference is transforming health care by making biomedical knowledge computable. Its partnership with Mayo Clinic has given nference an opportunity to synthesize decades of institutional knowledge, producing real-world evidence in real-time by converting large amounts of de-identified data into deep insights to advance discovery and development of diagnostics and therapeutics. Its proprietary AI-enabled software platform, nSights, has been used to accelerate life sciences research, development, and clinical care in significant ways, including biomarker discovery and validation, real-world evidence generation leveraging real-world data, early disease detection, public health policy generation and validation, and more. nference is headquartered in Cambridge, Mass.

Read More